BeyondSpring’s SEED Therapeutics appoints Tai to board of directors

SEED Therapeutics, a BeyondSpring (BYSI) subsidiary, announced that it has appointed Jackson Tai to its Board of Directors. Tai has most recently retired, or will soon retire, as a Non-Executive Director of Eli Lilly (LLY). He brings almost 50 years’ experience in finance, strategy, and risk governance to the SEED Therapeutics Board.